文献速递炎症性肠病

母亲炎症性肠病孕期暴露于硫嘌呤和抗TNF药物后75种主要先天性畸形的风险

Risks of 75 Major Congenital Malformations After In Utero Exposure to Thiopurines and Anti-TNF for Maternal Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-02-26

基于法国EPI-MERES注册数据库2010年4月至2021年12月39,515例炎症性肠病母亲分娩,比较孕早期暴露于硫嘌呤或抗TNF药物后75种主要先天性畸形风险。硫嘌呤暴露与任何主要先天性畸形均无一致关联;抗TNF暴露与马蹄内翻足风险升高相关(校正风险比2.17,95%CI 1.04-4.53),该发现需进一步研究确认。

要点

  • 硫嘌呤暴露未显示与75种主要先天性畸形中任何一种存在一致关联。
  • 抗TNF暴露与马蹄内翻足风险升高相关,校正风险比2.17(95%CI 1.04-4.53)。
  • 该马蹄内翻足发现需进一步研究确认。

核心结论

  • 本研究未发现宫内暴露于硫嘌呤或抗TNF药物与主要先天性畸形存在实质性风险的证据,但抗TNF暴露后马蹄内翻足风险似乎升高。
  • 该发现需在进一步研究中确认。

研究设计与样本

  • 基于法国全国综合性EPI-MERES注册数据库,纳入2010年4月至2021年12月炎症性肠病母亲中妊娠>22周的全部分娩。
  • 共39,515例分娩,其中硫嘌呤暴露5,223例、抗TNF暴露6,528例、未暴露28,827例。
  • 比较孕早期暴露于硫嘌呤和抗TNF后75种主要先天性畸形的风险,采用倾向评分加权校正母亲和妊娠特征,并进行敏感性分析评估估计稳健性。

主要发现

  • 共717例(181.5/10,000)发生≥1种主要先天性畸形。
  • 主要先天性畸形总体患病率:未暴露组175.2/10,000,硫嘌呤暴露组197.2/10,000,抗TNF暴露组203.7/10,000。
  • 在主分析和敏感性分析中,75种主要先天性畸形均未与硫嘌呤宫内暴露存在一致关联。
  • 抗TNF暴露与马蹄内翻足风险升高相关:主分析校正风险比2.17(95%CI 1.04-4.53),敏感性分析校正风险比范围为2.15至2.40。

局限性

  • 该发现需在进一步研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Limited data are available on the risk of major congenital malformations (MCMs) of thiopurines and anti-tumor necrosis factor (TNF) during pregnancy. In this study, we assess the risk of MCMs associated with maternal exposure to thiopurines and anti-TNF for the treatment of inflammatory bowel disease (IBD) during pregnancy. METHODS: Using the nationwide comprehensive EPI-MERES registry, we identified all births >22 weeks of pregnancy in mothers with IBD in France between April 2010 and December 2021. We compared the risks of 75 individual MCMs according to thiopurines and anti-TNF exposure during the first trimester of pregnancy, accounting for maternal and pregnancy characteristics using propensity score weighting. Sensitivity analyses were conducted to assess estimates robustness. RESULTS: Among a total of 39,515 births (5223 exposed to thiopurines, 6528 to anti-TNF, and 28,827 unexposed), 717 (181.5/10,000) had ≥1 MCM. The overall prevalence of MCMs ranged from 175.2 per 10,000 among unexposed births to 197.2 per 10,000 among those exposed to thiopurine, and 203.7 per 10,000 among those exposed to anti-TNF. None of the 75 MCMs was consistently associated with in utero exposure to thiopurines in the main and sensitivity analyses. However, anti-TNF exposure was associated with an increased risk of talipes equinovarus in the main analysis (adjusted risk ratio, 2.17; 95% confidence interval, 1.04-4.53) and in sensitivity analyses (adjusted risk ratios ranging between 2.15 and 2.40). CONCLUSIONS: This study provides no evidence of substantial risk of MCMs associated with in utero exposure to thiopurines or anti-TNF, except for talipes equinovarus, which appears increased with exposure to anti-TNF. This finding needs to be confirmed in further studies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Meyer A, Marty L, Drouin J, et al. Risks of 75 Major Congenital Malformations After In Utero Exposure to Thiopurines and Anti-TNF for Maternal Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40020958. doi:10.1016/j.cgh.2025.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。